Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2016 from OUS - Molecular Medicine (Sioud)
3 publications found
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Oncotarget, 7 (46), 75940-75953
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways
Oncotarget, 7 (29), 46187-46202